Christian Philipp Kamm
Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.
Gantenbein A, Bonvin C, Kamm C, Schankin C, Zecca C, Zieglgänsberger D, Merki-Feld G, Pohl H, Rudolph N, Ryvlin P, Agosti R, Schäfer E, Meyer I, Kulartz-Schank M, Arzt M. Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. J Neurol 2024
13.06.2024Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.
13.06.2024J Neurol 2024
Gantenbein Andreas R, Bonvin Christophe, Kamm Christian Philipp, Schankin Christoph J, Zecca Chiara, Zieglgänsberger Dominik, Merki-Feld Gabriele Susanne, Pohl Heiko, Rudolph Nicole, Ryvlin Philippe, Agosti Reto, Schäfer Elisabeth, Meyer Ina, Kulartz-Schank Monika, Arzt Michael E
Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS).
Achtnichts L, Zecca C, Findling O, Kamm C, Müller S, Kuhle J, Lutterotti A, Gobbi C, Viviani C, Villiger-Borter E, Nedeltchev K. Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS). BMJ Neurol Open 2023; 5:e000304.
26.01.2023Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS).
26.01.2023BMJ Neurol Open 2023; 5:e000304
Achtnichts Lutz, Zecca Chiara, Findling Oliver, Kamm Christian Philipp, Müller Stefanie, Kuhle Jens, Lutterotti Andreas, Gobbi Claudio, Viviani Camille, Villiger-Borter Emanuela, Nedeltchev Krassen
Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?
Rodgers S, Calabrese P, Ajdacic-Gross V, Steinemann N, Kaufmann M, Salmen A, Manjaly Z, Kesselring J, Kamm C, Kuhle J, Chan A, Gobbi C, Zecca C, Müller S, von Wyl V. Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?. J Psychosom Res 2021; 144:110402.
16.02.2021Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?
16.02.2021J Psychosom Res 2021; 144:110402
Rodgers Stephanie, Calabrese Pasquale, Ajdacic-Gross Vladeta, Steinemann Nina, Kaufmann Marco, Salmen Anke, Manjaly Zina-Mary, Kesselring Jürg, Kamm Christian Philipp, Kuhle Jens, Chan Andrew T, Gobbi Claudio, Zecca Chiara, Müller Stefanie, von Wyl Viktor
60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.
Kaufmann M, Puhan M, Salmen A, Kamm C, Manjaly Z, Calabrese P, Schippling S, Müller S, Kuhle J, Pot C, Gobbi C, Steinemann N, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR). 60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments. Front Neurol 2020; 11:156.
06.03.202060/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.
06.03.2020Front Neurol 2020; 11:156
Kaufmann Marco, Puhan Milo Alan, Salmen Anke, Kamm Christian Philipp, Manjaly Zina-Mary, Calabrese Pasquale, Schippling Sven, Müller Stefanie, Kuhle Jens, Pot Caroline, Gobbi Claudio, Steinemann Nina, von Wyl Viktor, Swiss Multiple Sclerosis Registry (SMSR)
How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
Barin L, Kamm C, Salmen A, Dressel H, Calabrese P, Pot C, Schippling S, Gobbi C, Müller S, Chan A, Rodgers S, Kaufmann M, Ajdacic-Gross V, Steinemann N, Kesselring J, Puhan M, von Wyl V, Swiss Multiple Sclerosis Registry. How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis. Mult Scler 2019; 26:489-500.
18.01.2019How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
18.01.2019Mult Scler 2019; 26:489-500
Barin Laura, Kamm Christian Philipp, Salmen Anke, Dressel Holger, Calabrese Pasquale, Pot Caroline, Schippling Sven, Gobbi Claudio, Müller Stefanie, Chan Andrew T, Rodgers Stephanie, Kaufmann Marco, Ajdacic-Gross Vladeta, Steinemann Nina, Kesselring Jürg, Puhan Milo Alan, von Wyl Viktor, Swiss Multiple Sclerosis Registry
A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity.
Puhan M, Steinemann N, Kamm C, Müller S, Kuhle J, Kurmann R, Calabrese P, Kesselring J, von Wyl V, Swiss Multiple Sclerosis Registry Smsr. A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity. Swiss Med Wkly 2018; 148:w14623.
16.05.2018A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity.
16.05.2018Swiss Med Wkly 2018; 148:w14623
Puhan Milo Alan, Steinemann Nina, Kamm Christian Philipp, Müller Stefanie, Kuhle Jens, Kurmann Roland, Calabrese Pasquale, Kesselring Jürg, von Wyl Viktor, Swiss Multiple Sclerosis Registry Smsr
Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial
Kamm C, Naegelin Y, Kappos L, Tettenborn B, Slotboom J, Müller F, Goebels N, Müller M, Donati F, Schött D, Schwegler G, Burren Y, von Bredow F, Findling O, Humpert S, El-Koussy M, Mattle H. Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial. J Neurol 2012; 259:2401-13.
09.05.2012Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial
09.05.2012J Neurol 2012; 259:2401-13
Kamm Christian Philipp, Naegelin Yvonne, Kappos Ludwig, Tettenborn Barbara, Slotboom Johannes, Müller Felix, Goebels Norbert, Müller Martin, Donati Filippo, Schött Dagmar, Schwegler Guido, Burren Yuliya, von Bredow Ferdinand, Findling Oliver, Humpert Sebastian, El-Koussy Marwan, Mattle Heinrich Paul
Hyponatremia associated coma due to pituitary apoplexy in early pregnancy: a case report
Krull I, Christ E, Kamm C, Ganter C, Sahli R. Hyponatremia associated coma due to pituitary apoplexy in early pregnancy: a case report. Gynecol Endocrinol 2010; 26:197-200.
01.03.2010Hyponatremia associated coma due to pituitary apoplexy in early pregnancy: a case report
01.03.2010Gynecol Endocrinol 2010; 26:197-200
Krull Ina, Christ Emanuel, Kamm Christian Philipp, Ganter Christoph, Sahli Rahel
SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.
Kamm C, Mattle H, De Marchis G. SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology. Trials 2009; 10:115.
14.12.2009SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.
14.12.2009Trials 2009; 10:115
Kamm Christian Philipp, Mattle Heinrich Paul, De Marchis Gian Marco